• First-in-class peptidomimetic with distinct MoA activating trophic signaling pathways to protect and prevent damage to the optic nerve and retina
  • Potential to be disease modifying in lead indications such as glaucoma, geographic atrophy, acute optic neuritis (AON) and other optic neuropathies
  • Proof of concept (PoC) clinical trial in progress for AON with results due 2H23
  • Agreement supports Oculis’s mission to become a global ophthalmology leader bringing breakthrough innovations to the top three segments of the market: retina, dry eye and glaucoma
  • Deal validates Accure’s strategy as a translational R&D engine in neuroscience
TAGS:

About the author.

administrator

20 years of experience in international business development in the pharmaceutical industry. Head of commercial operations and business development for Bristol-Myers Squibb in 16 Latin American countries. Global management consultant. Speaks French and Spanish fluently. Completed nine transactions in global markets in the past three years.

No Comments. Leave a comment  

Leave a Reply

Your email address will not be published.

TYPE & ENTER: